Design of the Efficacy of Prednisone in the Treatment of Ocular Myasthenia (EPITOME) trial

Annals of the New York Academy of Sciences

Volumn 1275, Issue 1, 2012, Pages 17-22

  Benatar, Michael ^a   Sanders, Donald B ^b   Wolfe, Gil I ^c   McDermott, Michael P ^d   Tawil, Rabi ^d  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

^d UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Clinical trial; Evidence based medicine; Ocular myasthenia; Steroids

Indexed keywords

PLACEBO; PREDNISONE; PYRIDOSTIGMINE;

ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; HUMAN; MULTICENTER STUDY; MYASTHENIA GRAVIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 84871591629     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2012.06780.x     Document Type: Article

References (27)

1. Ferguson, F.R., E.C. Hutchinson & L.A. Liversedge. 1955. Myasthenia gravis; results of medical management. Lancet 269: 636-639.
2. Robertson, N., J. Deans & D. Compston. 1998. Myasthenia gravis: a population based epidemiological study in Cambridgeshire, England. J. Neurol. Neurosurg. Psychiatr. 65: 492-6.
3. Weizer, J.S., A.G. Lee & D.K. Coats. 2001. Myasthenia gravis with ocular involvement in older patients. Can. J. Ophthalmol. 36: 26-33.
4. Bever, C.T., A.V. Aquino, A.S. Penn, et al. 1983. Prognosis of ocular myasthenia. Ann. Neurol. 14: 516-519.
5. Christensen, P.B., T.S. Jensen, I. Tsiropoulos, et al. 1993. Incidence and prevalence of myasthenia gravis in western Denmark: 1975 to 1989. Neurology 43: 1779-1783.
6. Casetta, I., E. Fallica, V. Govoni, et al. 2004. Incidence of myasthenia gravis in the province of Ferrara: a community-based study. Neuroepidemiology 23: 281-284.
7. Lavrnic, D., M. Jarebinski, Rakocevic-Stojanovic V, et al. 1999. Epidemiological and clinical characteristics of myasthenia gravis in Belgrade, Yugoslavia (1983-1992). Acta Neurologica Scandinavica 100: 168-174.
8. Phillips, L.H., J.C. Torner, M.S. Anderson & G.M. Cox. 1992. The epidemiology of myasthenia gravis in central and western Virginia. Neurology 42: 1888-1893.
9. anonymous. 1998. Incidence of myasthenia gravis in the Emilia-Romagna region: a prospective multicenter study. Emilia-Romagna Study Group on Clinical and Epidemiological Problems in Neurology. Neurology 51: 255-258.
10. Aiello, I., M. Pastorino, S. Sotgiu, et al. 1997. Epidemiology of myasthenia gravis in northwestern Sardinia. Neuroepidemiol. 16: 199-206.
11. Benatar, M. & H. Kaminski. 2006. Medical and surgical treatments for ocular myasthenia. Cochrane Database Syst. Rev. Apr. 19; (2): CD005081.
12. Benatar, M. & H.J. Kaminski. 2007. Evidence report: the medical treatment of ocular myasthenia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 68: 2144-2149.
13. Kupersmith, M.J., R. Latkany & P. Homel. 2003. Development of generalized disease at 2 years in patients with ocular myasthenia gravis. Arch. Neurol. 60: 243-248.
14. Mee, J., M. Paine, E. Byrne, et al. 2003. Immunotherapy of ocular myasthenia gravis reduces conversion to generalized myasthenia gravis. J. Neuroophthalmol. 23: 251-255.
15. Monsul, N.T., H.S. Patwa, A.M. Knorr, et al. 2004. The effect of prednisone on the progression from ocular to generalized myasthenia gravis. J. Neurol. Sci. 217: 131-133.
16. Papapetropoulos, T.H., J. Ellul & E. Tsibri. 2003. Development of generalized myasthenia gravis in patients with ocular myasthenia gravis. Arch. Neurol. 60: 1491-1492.
17. Sommer, N., B. Sigg, A. Melms, et al. 1997. Ocular myasthenia gravis: response to long-term immunosuppressant treatment. J. Neurol. Neurosurg. Psychiatr. 62: 156-162.
18. Bhanushali, M., J. Wuu & M. Benatar. 2008. Treatment of ocular myasthenia. Neurology 71: 1335-1341.
19. Agius M. 2000. Treatment of ocular myasthenia with corticosteroids: yes. Arch. Neurol. 57: 750-751.
20. Hachinski V. 2000. Treatment of ocular myasthenia. Arch. Neurol. 57: 753.
21. Kaminski, H. & R. Daroff. 2000. Treatment of ocular myasthenia: steroids only when compelled. Arch. Neurol. 57: 752-753.
22. Jaretzki, A., R. Barohn, R. Ernstoff, et al. 2000. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology 55: 16-23.
23. Sanders, D.B., B. Tucker-Lipscomb & J.M. Massey. 2003. A simple manual muscle test for myasthenia gravis: validation and comparison with the QMG score. Ann. N.Y. Acad. Sci. 998: 440-444.
24. Mangione, C.M., P.P. Lee, P.R. Gutierrez, et al. 2001. Development of the 25-item National Eye Institute Visual Function Questionnaire. Arch. Ophthalmol. 119: 1050-1058.
25. Raphael, B.A., K.M. Galetta, D.A. Jacobs, et al. 2006. Validation and test characteristics of a 10-item neuro-ophthalmic supplement to the NEI-VFQ-25. Am. J. Ophthalmol. 142: 1026-1035.
26. Burns, T.M., M.R. Conaway, G.R. Cutter & D.B. Sanders. 2008. Less is more, or almost as much: a 15-item quality-of-life instrument for myasthenia gravis. Muscle Nerve 38: 957-963.
27. Benatar, M., D.B. Sanders, T.M. Burns, et al. 2012. Recommendations for myasthenia gravis clinical trials. Muscle Nerve 45: 909-917.